ACROBiosystems’ Post

For an insightful webinar about organoids and how ACROBiosystems' organoid solutions revolutionize the pharmaceutical landscape, feel free to go register 👇

𝐔𝐧𝐥𝐨𝐜𝐤𝐢𝐧𝐠 𝐭𝐡𝐞 𝐏𝐨𝐭𝐞𝐧𝐭𝐢𝐚𝐥 𝐨𝐟 𝐀𝐃𝐂𝐬 𝐢𝐧 𝐃𝐫𝐮𝐠 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 This insightful article is featured in "𝐏𝐡𝐚𝐫𝐦𝐚 𝐅𝐨𝐜𝐮𝐬 𝐄𝐮𝐫𝐨𝐩𝐞 𝐌𝐚𝐠𝐚𝐳𝐢𝐧𝐞 𝐈𝐬𝐬𝐮𝐞 𝟎𝟒." 𝐀𝐧𝐭𝐢𝐛𝐨𝐝𝐲-𝐝𝐫𝐮𝐠 𝐜𝐨𝐧𝐣𝐮𝐠𝐚𝐭𝐞𝐬 (𝐀𝐃𝐂𝐬)  represent one of the fastest-growing modalities in the pharmaceutical industry, merging the precision of targeted antibodies with the power of cytotoxic payloads. This innovative combination offers significant therapeutic benefits, especially in oncology. At Veranova, our experts, led by Kishore Hotha, PhD, MBA, are at the forefront of ADC development. We understand the intricate challenges involved and leverage advanced techniques, such as preparative chromatography, to streamline the process. This not only enhances efficiency but also ensures the delivery of high-quality, effective treatments to patients. Join us in exploring the 𝐟𝐮𝐭𝐮𝐫𝐞 𝐨𝐟 𝐀𝐃𝐂𝐬  and how we can overcome development hurdles to bring groundbreaking therapies to market. Click the link below to learn more about our comprehensive ADC development services. 🔗 𝐋𝐞𝐚𝐫𝐧 𝐌𝐨𝐫𝐞: https://lnkd.in/eRKBNVmS 🔗 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐭𝐡𝐞 𝐞-𝐛𝐨𝐨𝐤 𝐧𝐨𝐰: https://lnkd.in/gv7R4SPi #Pharmaceuticals #DrugDevelopment #ADCs #Biotechnology #Oncology #Therapeutics #Innovations #Healthcare #PharmaResearch #PrecisionMedicine #AntibodyDrugConjugates #Veranova #PreparativeChromatography #DrKishoreHotha #PharmaExperts

What are the challenges in adopting new analytical technologies seamlessly for cell therapy drug products? Join Alice Lin & others for a roundtable discussion on the topic at our Advanced Therapies Roundtable Xchange happening in San Diego, February 29th 2024. She'll also be sharing case studies and best practices with real-world examples. Not to be missed! To view all facilitators, agendas, registration info and more, please visit: https://lnkd.in/eQAUQU7Y Note: Registration is only open to Senior Scientists and above actively working in the pharmaceutical/biotech industry. Each roundtable is limited to 8 participants. #hubXchangeNotAConference #pharma #drugdiscovery #biotech #bigdata #datasciences #lifesciences #drugdevelopment #pharmacology #clinicaldevelopment #clinicalstudies #clinicaltrials #biomarkers #oncology #genomics #pharmaceutical #advancedtherapies #manufacturing #therapeutics #therapies #oligonucleotide #genetherapies

Explore the depths of antibody structure by downloading our latest app note! This study focuses on the structural analysis of #mAbs, shedding light on their mechanisms and therapeutic potential. Using Microfluidic Modulation Spectroscopy (MMS), we examined the secondary structure of IgG1, IgG2, IgG3, and IgG4 in #formulation conditions. Our findings reveal distinct characteristics among these subclasses, paving the way for targeted therapies and drug development. Download: https://lnkd.in/emfzhbHE Thanks to our study contributors: David Gillingham, Richard Hailin Huang, Ph.D., Valerie Ivancic Collins, Ph.D., and our contributors at ACROBiosystems: Larry Yu, Spencer Chiang, and Michael M. Friedman Hear more from the study authors in our upcoming webinar on MMP characterization for biomarker discovery! https://lnkd.in/eastvPtv #targetedtherapy #drugdevelopment #spectroscopy #antibodies #antibodytherapeutics #biologics #biopharmaceutical #biopharma #biopharmaceuticals #research #newresearch #biotherapeutics #HOS #proteins #characterization #mab

InMed CEO Eric A. Adams comments on the company's preclinical research demonstrating promising effects in #Alzheimers Disease and Age-related #Macular #Degeneration. #AMD “As we embark on 2024, we are placing increased emphasis on proprietary small molecule drug development candidates in our pharmaceutical pipeline with two exciting new programs addressing critical unmet medical needs. Firstly, INM-901 for the treatment of Alzheimer’s disease is showing promise via multiple mechanisms of action, including an increase in neuroprotection and an improvement in neuronal function via neuritogenesis. Secondly, INM-089 for the treatment of AMD appears to play a role in the preservation of retinal function, proactively protecting the retinal cells that are responsible for vision. Our focus on developing proprietary cannabinoid analogs over the past two years has started to pay dividends, evident in their utilization in these two new preclinical programs.” Read news release: https://ow.ly/2n0A50Qr4yg $INM #cannabinoids #research #drugdevelopment #pharma

At this year's AACR Annual Meeting, Arvinas, a pioneer in PROTAC technology, sponsored a session titled "From Chemistry to Clinic," focusing on PROTAC and ADC technologies and the breakthroughs achieved by their combination. The presentation by Marcel Rieker, a scientist from Merck Germany, sparked widespread interest and discussion. His talk revolved around an exciting concept: combining two cutting-edge drug discovery fields, PROTAC and ADC, to explore a new strategy for delivering degraders to diseased cells. The PROTAC-ADCs (Antibody Drug Conjugates) and self-assembling PROxAb shuttles presented by Marcel Rieker at the AACR 2024 meeting represent a significant innovation of PROTAC technology in the field of drug delivery system design. Through this research, it was demonstrated how to enhance the selectivity and efficacy of drugs against specific targets, which is of great significance for cancer treatment. #APIs #Medical #Rawmaterials #Pharma #Medicine #Pharmaceutical

Happy to share that Insilico Medicine and invoX Pharma - a research-driven global biopharma company - have announced a new strategic partnership to boost InvoX Pharma's anti-cancer pipeline for potential indications expansion. The collaboration is set to leverage Insilico's expertise in AI drug discovery, as well as InvoX's experience in drug development and data science. Specifically, the partnership will use Insilico's independently-developed target discovery engine, PandaOmics®, in combination with InvoX's internal drug development team's experience. This partnership aims to analyze existing InvoX pipelines to identify new potential indications, and further assess the feasibility of candidate drugs for potential indication treatments. #QMportfolio #QMhealthcare #insilicomedicine #InvoXPharma #StrageticPartnership #DrugDiscovery #AI #PandaOmics #CancerResearch #Biopharmaceuticals #DataScience

What are the challenges in adopting new analytical technologies seamlessly for cell therapy drug products? Join Alice Lin & others for a roundtable discussion on the topic at our Advanced Therapies Roundtable Xchange happening in San Diego, February 29th 2024. She'll also be sharing case studies and best practices with real-world examples. Not to be missed! To view all facilitators, agendas, registration info and more, please visit: https://lnkd.in/dcuUeiVC Note: Registration is only open to Senior Scientists and above actively working in the pharmaceutical/biotech industry. Each roundtable is limited to 8 participants. #hubXchangeNotAConference #pharma #drugdiscovery #biotech #bigdata #datasciences #lifesciences #drugdevelopment #pharmacology #clinicaldevelopment #clinicalstudies #clinicaltrials #biomarkers #oncology #genomics #pharmaceutical #advancedtherapies #manufacturing #therapeutics #therapies #oligonucleotide #genetherapies

I am thrilled to share the launch of our website for The Synaptic Gap! 🌐 At The Synaptic Gap, we specialize in offering strategic scientific advice, effective communication solutions, and comprehensive business development services tailored to the pharmaceutical sector. Whether you're in the early stages of developing groundbreaking compounds or products aimed at improving patient care, or you're a established biotech or pharmaceutical company seeking enhanced support for your existing platforms, we're here to assist you every step of the way. Visit our website to learn more about how we can collaborate to drive innovation and success in the pharmaceutical industry! #TheSynapticGap #PharmaceuticalInnovation #ScienceAndStrategy

🚀 Registration Now Open for the Oligonucleotide Therapeutics Xchange - Maryland 2024! 🚀 We are thrilled to share that registration is now open for hubXchange's Oligonucleotide Therapeutics Xchange Maryland 2024! This event will convene leading executives from the pharma and biotech sectors to tackle and find solutions for the critical challenges in Oligonucleotide Therapeutics. 📅 Date: Wednesday, October 30, 2024 🕗 Time: 8:00 AM - 6:15 PM 📍 Location: Maryland Join us to stay at the forefront of Oligonucleotide Therapeutics innovation and connect with fellow industry leaders. Don’t miss out—register today and get your Complimentary Pass! https://lnkd.in/eyChA_wt 🔎 Why Attend hubXchange? Take advantage of a unique platform that promotes knowledge exchange and industry connections. 🗣🔬 Featuring Industry Experts: Weiguo Zhai, Senior Director, R&D Analytical Sciences, BioPharmaceutical Development, AstraZeneca Xiaoyong Lu, M.S. Ph.D., Director of Oligonucleotide and Genetic Medicine, Eli Lilly and Company Antonio DiGiandomenico, Senior Director, AstraZeneca Jimmy Weterings, VP, Research RNA Therapeutics & Delivery, Sirnaomics Jeremy Little, Director of Custom Oligonucleotides, ChemGenes Trishul Shah, Director Business Development, Head of Sales North America, PolyPeptide Group Jeremy Little, Director of Custom Oligonucleotides, ChemGenes David Brown, Director, RNAimmune David Blackmon, Director, Alcyone Therapeutics Inc. Our Partners: 🤝 ChemGenes 🤝 PolyPeptide Group 💊 Only available for Senior Scientists and above, from Bio and Pharma companies, with a drug pipeline. 💊 #OligonucleotideTherapeutics #Pharma #Biotech #hubXchange #Networking #Innovation #MarylandEvent #DrugDevelopment #RNAtherapeutics #GeneticMedicine #Biopharma #Pharmaceuticals #Biotechnology #LifeSciences #MedicalResearch #HealthcareInnovation #BiotechCommunity #ScientificConference #Therapeutics #BiotechInnovation #PharmaConference #ClinicalResearch #DrugDelivery #NewModalities #OligonucleotideDiscovery #PharmaNetworking #PharmaEvents #Xchanges #Roundtable #FreePass #RegisterNow #ComplimentaryPass